- Home
- Automated
- List of product information
- AQUIPTA TABLET 60MG [SIN17146P]
AQUIPTA TABLET 60MG [SIN17146P]
Active ingredients: AQUIPTA TABLET 60MG
Last updated 26 October 2025
On this page
Product Info
AQUIPTA TABLET 60MG
[SIN17146P]
Product information
Active Ingredient and Strength | ATOGEPANT MONOHYDRATE EQV ATOGEPANT - 60 MG |
Dosage Form | TABLET |
Manufacturer and Country | FOREST LABORATORIES IRELAND, LIMITED - IRELAND |
Registration Number | SIN17146P |
Licence Holder | ABBVIE PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | N02CD07 |
2. INDICATIONS
AQUIPTA™ is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.
3. DOSAGE AND ADMINISTRATION
3.1 Recommended dosage
The recommended dose for AQUIPTA™ is 60 mg taken orally once daily with or without food.
There is no data that the 60 mg tablet can be divided into equal halves.
3.2 Missed dose
A missed dose should be taken right away. If it is almost time for the next dose, patients should be instructed to skip the missed dose and take the next dose as scheduled.
3.3 Dose modification
Dosing modifications for concomitant use of specific drugs (see DRUG INTERACTIONS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information) and for patients with renal impairment are provided in Table 1.
3.4 Dosing in special populations
3.4.1 Pediatrics
Safety and effectiveness of AQUIPTA™ in pediatric patients have not been established.
3.4.2 Geriatric
Population pharmacokinetic modeling suggests no clinically significant pharmacokinetic differences between elderly and younger subjects. No dose adjustment of AQUIPTA™ is needed in elderly patients.
3.4.3 Renal impairment
For patients with severe renal impairment and ESRD, see dose adjustment in Table 1. No dose adjustment is recommended for patients with mild or moderate renal impairment.
For patients with ESRD undergoing intermittent dialysis, AQUIPTA™ should preferably be taken after dialysis.
3.4.4 Hepatic impairment
Avoid use of AQUIPTA™ in patients with severe hepatic impairment (Child-Pugh Class C) (see PHARMACOLOGIC PROPERTIES – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). No dose adjustment is recommended for patients with mild (Child-Pugh Class A) or moderate (Child Pugh Class B) hepatic impairment.
4. CONTRAINDICATIONS
AQUIPTA™ is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of AQUIPTA™. Reactions have included anaphylaxis and dyspnea (see WARNINGS AND PRECAUTIONS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).